AI filing briefs · archive

8-K filings in September 2026, explained

1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,853 briefs match

newest first · times in ET

ESLAEstrella Immunopharma, Inc. Sep 8, 5:25 PM ET

Estrella Immunopharma gets Nasdaq notice for below-minimum market value; 180 days to comply

Negative legal/regulatory Written later 3.01

Estrella Immunopharma received a Nasdaq notice on September 1, 2026, stating its market value of listed securities fell below the $35 million minimum for 30 consecutive business days. The company has until March 1, 2027 to regain compliance, and the stock continues to trade on Nasdaq for now, but failure to comply could lead to delisting proceedings.

Nasdaq notice dated September 1, 2026 cites market value of listed securities below $35,000,000 for 30 consecutive business days, July 21 through August 31, 2026
Company does not meet Nasdaq's alternative standards for stockholders' equity of at least $2,500,000 or net income of at least $500,000
Compliance deadline is March 1, 2027; regaining compliance requires closing at $35,000,000 or more for at least ten consecutive business days
Common stock continues to trade on The Nasdaq Capital Market under the symbol ESLA

Read the filing on SEC.gov ↗

NTLAIntellia Therapeutics, Inc. Sep 8, 4:05 PM ET

Intellia FDA accepts lonvo-z BLA with Priority Review; PDUFA date March 10, 2027

Positive legal/regulatory Written later 7.01 8.01

Intellia Therapeutics said the FDA accepted its Biologics License Application for lonvo-z, its investigational one-time treatment for hereditary angioedema, and granted Priority Review with a PDUFA target action date of March 10, 2027. The FDA also said it does not currently plan to hold an advisory committee meeting on the application. The milestone sets a defined regulatory timeline for a product the company says could be the first approved in vivo CRISPR-based therapy.

FDA accepted the BLA for lonvo-z and granted Priority Review
PDUFA target action date is March 10, 2027
FDA does not currently plan an advisory committee to discuss the application
Phase 3 HAELO trial met its primary and all key secondary endpoints, with an 87% reduction in mean monthly attacks versus placebo

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.